2021
DOI: 10.1038/s41419-021-04029-4
|View full text |Cite
|
Sign up to set email alerts
|

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer

Abstract: Conventional chemotherapy is still of great utility in oncology and rationally constructing combinations with it remains a top priority. Drug-induced mitochondrial apoptotic priming, measured by dynamic BH3 profiling (DBP), has been shown in multiple cancers to identify drugs that promote apoptosis in vivo. We therefore hypothesized that we could use DBP to identify drugs that would render cancers more sensitive to conventional chemotherapy. We found that targeted agents that increased priming of non-small cel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
18
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 21 publications
(19 citation statements)
references
References 26 publications
1
18
0
Order By: Relevance
“…In squamous cell lung carcinoma, dual inhibition of MCL-1 and BCL-XL induced synergistic tumour cell death, and when combined with fibroblast growth factor receptor (FGFR)-targeted therapy, produced durable treatment responses in FGFR1- overexpressing lung squamous cell carcinoma [ 79 ]. Similar results were also observed in malignant pleural mesothelioma, NSCLC and colorectal cancer [ 8 , 12 , 19 , 40 , 80 , 81 ]. In these cancers, BCL-XL is the dominant survival factor as its sole targeting had a greater effect compared with the targeting of MCL-1 alone.…”
Section: Targeting Multiple Pro-survival Proteins With Bh3-mimetics For Solid Cancer Treatmentsupporting
confidence: 83%
See 1 more Smart Citation
“…In squamous cell lung carcinoma, dual inhibition of MCL-1 and BCL-XL induced synergistic tumour cell death, and when combined with fibroblast growth factor receptor (FGFR)-targeted therapy, produced durable treatment responses in FGFR1- overexpressing lung squamous cell carcinoma [ 79 ]. Similar results were also observed in malignant pleural mesothelioma, NSCLC and colorectal cancer [ 8 , 12 , 19 , 40 , 80 , 81 ]. In these cancers, BCL-XL is the dominant survival factor as its sole targeting had a greater effect compared with the targeting of MCL-1 alone.…”
Section: Targeting Multiple Pro-survival Proteins With Bh3-mimetics For Solid Cancer Treatmentsupporting
confidence: 83%
“…However, given the key and often compensatory roles these proteins play in non-malignant cells, co-inhibition of two or more pro-survival proteins potentiates the opportunity for associated toxicities. The simultaneous disarmament of BCL-XL and MCL-1 with BH3-mimetics in mice is lethal due to acute liver toxicity [ 12 , 79 ] as both these proteins are critical for hepatocyte survival [ 88 ]. These pro-survival proteins are also essential for megakaryocyte survival [ 89 ].…”
Section: Circumventing Toxicities Associated With Bh3-mimetic Combinationsmentioning
confidence: 99%
“…To solve this problem, a new microscopy-based version created by the Letai lab, called highthroughput DBP (HT-DBP), has been developed using 384 well plates, automatic multi-well dispensers, and automated highthroughput fluorescence microscopes. This method uses approximately 5k cells per treatment and has been successfully utilized to screen hundreds of anticancer drugs in colon cancer 23 and nonsmall cell lung cancer 59 patients. However, HT-DBP requires a predetermination of the optimal BIM peptide concentration (demanding more time than μDBP and around 250k more cells), expensive equipment, and highly trained personnel to be performed; thus, it has to be centralized in a specialized laboratory, hampering its broad application in the clinic.…”
Section: Discussionmentioning
confidence: 99%
“…Indeed, the ability of cancer therapeutics to prime individual cancers for apoptosis can be gauged ex vivo using an adapted BH3-profiling protocol [ 138 ]. The utility of inhibiting different pro-survival BCL-2 proteins in combination with chemotherapy has been demonstrated using freshly isolated non-small cell lung cancer patient samples [ 139 ]. It can be envisioned that such technologies could pave the way for personalized use of BH3 mimetics in breast cancer.…”
Section: Mcl-1 Is Required For Breast Cancer Cell Survivalmentioning
confidence: 99%